Is Pertuzumab an immune drug or a targeted drug?

Pertuzumab (Pertuzumab), also known by its trade name Perjeta, is a targeted cancer drug that is used to treat breast cancer before surgery (neoadjuvant therapy), after surgery (adjuvant therapy), for breast cancer that has spread (secondary breast cancer), and for breast cancer that has come back in the breast (recurrent breast cancer).

Pertuzumab is a monoclonal antibody that works by attaching to a protein on or in cancer cells. Human epidermal growth factor2 (HER2) is a protein that makes cells grow and divide. Some cancers have large amounts of the HER2 protein and are called HER2-positive cancers. Pertuzumab works by locking HER2 on cancer cells. This will stop them from growing and kill them. Pertuzumab is only effective when the cancer is HER2-positive, and is often used in combination with the targeted drug trastuzumab and taxane-containing chemotherapy. Each treatment takes 30 to 60 minutes, with the first treatment taking more than 60 minutes and, if progress goes well, the next treatment may take more than 30 to 60 minutes.

Pertuzumab is a strictly controlled drug. The original drug has been marketed in China and has entered the ranks of medical insurance, but it is only reimbursed for patients who meet the indications. The price of each box may be more than more than 5,000 yuan, and the price of the Hong Kong version may be more than 20,000 yuan (the price may fluctuate due to exchange rates). The price of each box of the European version of Pertuzumab's original drug marketed overseas may be more than 10,000 yuan, and the price of each box of the Turkish version may be more than 6,000 yuan (the price may fluctuate due to exchange rates). The ingredients of the domestic and foreign original drugs are basically the same, and there are currently no generic versions of Pertuzumab on the market.